Abstract:Background: Lysophosphatidic acid (LPA) is an important extracellular signal transmitter and intracellular second messenger in body fluids. It can be detected in the ascitic fluid of patients with ovarian cancer. Increasing evidence shows that LPA can stimulate cancer cell proliferation and promote tumor invasion and metastasis. Our study aimed to evaluate the diagnostic value of LPA in differentiating between malignant pleural effusions (MPEs) and benign pleural effusions (BPEs) and to evaluate the association between the level of LPA in MPE and the prognosis of lung cancer patients.Patients and methods: The level of LPA in the pleural effusions (PEs) of 123 patients (94 MPE, 29 BPE) with lung cancer was evaluated using an enzyme-linked immunosorbent assay. The performance of LPA was analyzed by standard Receiver operator characteristic curve (ROC) analysis methods, using the area under the curve (AUC) as a measure of accuracy. Overall survival (OS) curves and progression-free survival (PFS) curves were based on the Kaplan-Meier method, and the survival differences between subgroups were analyzed using the log-rank or Breslow test (SPSS software). A multivariate Cox proportional hazards model was used to assess whether LPA independently predicted lung cancer survival.Results: The levels of LPA differed significantly between MPE (22.08 +/- 8.72 mu g/L) and BPE (14.61 +/- 5.12 mu g/L) (P<0.05). Using a cutoff point of 18.93 mu g/L, LPA had a sensitivity of 60% and a specificity of 83% to distinguish MPEs from BPEs with an AUC of 0.769 +/- 0.045 (SE) (P=0.000) (95% CI, 0.68-0.857). In the three pathological types of lung cancer patients with MPE, there were no significant associations between LPA levels and the length of PFS and OS (P=0.58 and 0.186, respectively). Interestingly, in the patients with MPE caused by lung adenocarcinoma there were significant associations between the LPA levels and the PFS and OS (P=0.018 and 0.026, respectively). Multivariate analysis showed that the LPA level was an independent prognostic factor for PFS in lung adenocarcinoma.Conclusions: Our results indicate that LPA can be used as a new biomarker for the diagnosis of MPE caused by lung cancer and that higher levels of LPA are related to shorter PFS in adenocarcinoma of the lung.

Elevated Hsp90-beta Contributes to Differential Diagnosis of Pleural Effusion Caused by Lung Cancer and Correlates with Malignant Biological Behavior of Lung Cancer

Differential Proteome Profiling of Pleural Effusions from Lung Cancer and Benign Inflammatory Disease Patients

Increased Level of Hsp90-Beta in Bronchoalveolar Lavage Fluid Correlates with Lymphatic Invasion and Advanced Stage of Lung Cancer Patients

Identification and verification of Hsp90-beta as a potential serum biomarker for lung cancer (vol 4, pg 874, 2014)

SPP1 expressed in malignant pleural effusion in patients with advanced lung cancer and its value for diagnosis

Expression of Hsp90α in blood of patients with lung cancer

Elevation of Serum HSP90α Correlated with the Clinical Stage of Non-Small Cell Lung Cancer

Significance of serum and pleural effusion levels of related factors in differential diagnosis of tuberculosis and malignant tumor

Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment Responses.

The Diagnostic Value of MCP-1 and RANTES in Tuberculosis and Malignant Pleural Effusion

Diagnostic value of HSP90α and Related Markers in Lung Cancer

Application of detecting tumor M2-PK and CEA in pleural effusion for clinical diagnosis of malignant pleural effusion caused by lung cancer

Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis.

Auxiliary diagnostic value of tumor biomarkers in pleural fluid for lung cancer-associated malignant pleural effusion

Clinical Value of Haptoglobin and Soluble CD163 Testing for the Differential Diagnosis of Tuberculous and Malignant Pleural Effusions.

Diagnostic and Prognostic Values of Endothelial-Cell-Specific Molecule-1 with Malignant Pleural Effusions in Patients with Non-Small Cell Lung Cancer

Quantitative proteomics revealed protein biomarkers to distinguish malignant pleural effusion from benign pleural effusion

Diagnostic and Prognostic Significance of Lysophosphatidic Acid in Malignant Pleural Effusions.

Plasma heat shock protein 90 alpha in the diagnosis and treatment of breast cancer

Diagnostic value of soluble B7-H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion.